Erbitux is an injectable antineoplastic agent that helps stop the growth of cancer cells. This medication can only be used according to the doctor’s instructions and is intended for hospital use only.
This medicine is usually applied by a nurse to a vein once a week to monitor the development of cancer.
This medicine is recommended for the treatment of colon cancer, rectal cancer, head cancer and neck cancer.
Erbitux is injected into the vein administered by the hospital nurse, usually to control the development of the tumor is applied once a week, in most cases the initial dose is 400 mg cetuximab per m2 of body surface area and all subsequent weekly doses. 250 mg cetuximab per m2 each.
In addition, careful monitoring is required during administration of the drug and up to 1 hour after application. Before infusion, other medicines such as antihistamines and a corticosteroid should be given at least 1 hour before cetuximab.
Some side effects of using this medicine include swelling, abdominal pain, lack of appetite, constipation, poor digestion, difficulty swallowing, mucite, nausea, inflammation of the mouth, vomiting, dry mouth, anemia, decreased white blood cells, dehydration. , weight loss, back pain, conjunctivitis, hair loss, rash, nail problems, itching, skin allergy to radiation, coughing, , weakness, depression, fever, headache, insomnia, chills, infection and pain.
The use of this medicine is contraindicated during pregnancy, during lactation and hypersensitivity to one of the components of the medicine.